by Combat Cancer | Feb 17, 2024 | News
Bladder cancer, the 11th most common malignancy in the UK, is often diagnosed late or misdiagnosed, particularly in women. This delayed or incorrect diagnosis can have significant impacts on patient outcomes, as early-stage bladder cancer has a much better prognosis...
by Combat Cancer | Feb 8, 2024 | News
According to the World Health Organization (WHO), cancer is the second leading cause of death globally, and pancreatic cancer is among the most deadly forms of the disease. The prognosis for pancreatic cancer is particularly poor, with a five-year survival rate of...
by Combat Cancer | Feb 1, 2024 | News
World Cancer Day, observed on 4th February each year, marks a global initiative led by the Union for International Cancer Control (UICC). This day is dedicated to raising worldwide awareness, improving education, and helping to kickstart personal, collective, and...
by Combat Cancer | Jan 27, 2024 | News
RC is recommended for patients with non-muscle-invasive bladder cancer for whom BCG immunotherapy has failed – that’s around 50% of high-risk cases. However, many patients are unwilling to undergo RC because of its impact on quality of life. While bladder cancer...
by Combat Cancer | Jan 19, 2024 | News
Bladder cancer is among the most common types of cancer, with varying degrees of invasiveness. Non-muscle-invasive bladder cancer (NMIBC) is a subtype where cancer cells are confined to the surface layers of the bladder wall and have not invaded the muscle layer. This...
by Combat Cancer | Jan 11, 2024 | News
Shaping the Future of Bladder Cancer Care Hosted by MEP Isátv Ujhelyi, a momentous policy roundtable was convened on 25 September 2023, where the white paper’s recommendations were unveiled. The discussion was centred around identifying legislative opportunities...
Recent Comments